Corvus Pharmaceuticals News

Express News | Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

Reuters16:02 ET

Express News | Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

ReutersMay 2 08:30 ET

Express News | Corvus Pharmaceuticals-Co & Jefferies Entered Into an Amendment to Sales Agreement Pursuant to Which Aggregate Offering Price Was Reduced to $8.2 Mln

ReutersMay 1 17:23 ET

Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings

All three major Wall Street indexes were down in late-morning trading Tuesday in the wake of higher-than-expected employment cost data and ahead of the Federal Open Market Committee's decision on rate

MT NewswiresApr 30 11:59 ET

Corvus Janitorial Systems Recognized by Entrepreneur Magazine as a Leading Franchise Opportunity in 2024

WESTLAKE, Ohio, April 29, 2024 /PRNewswire/ -- Corvus Janitorial Systems, a leader in commercial cleaning services, is proud to announce its remarkable achievements as recognized by Entrepreneur Maga

PR NewswireApr 29 07:37 ET

12 Health Care Stocks Moving In Tuesday's After-Market Session

GainersJaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. aTyr Pharma (NASDAQ:LIFE) shares rose 10.45% to $

BenzingaApr 9 16:31 ET

Corvus Pharmaceuticals Announces Initiation Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis

Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's selective ITK inhibitorCorvus anticipates releasing initial clinical data from tria

BenzingaApr 9 16:02 ET

Cantor Fitzgerald Reiterates Overweight on Corvus Pharma

Cantor Fitzgerald analyst Li Watsek reiterates Corvus Pharma (NASDAQ:CRVS) with a Overweight.

BenzingaApr 1 11:16 ET

Express News | Mizuho Maintains Neutral on Corvus Pharma, Maintains $3.5 Price Target

Moomoo 24/7Mar 27 13:21 ET

Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?

Yahoo FinanceMar 22 12:00 ET

Corvus Pharmaceuticals: Insider Ownership Raises Power Concentration Concerns

TipRanksMar 21 02:01 ET

Corvus Pharmaceuticals Is Maintained at Outperform by Oppenheimer

Corvus Pharmaceuticals Is Maintained at Outperform by Oppenheimer

Dow JonesMar 20 07:24 ET

Express News | Oppenheimer Maintains Outperform on Corvus Pharma, Lowers Price Target to $7

Moomoo 24/7Mar 20 07:14 ET

Corvus Pharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/20/2024 246.53% Oppenheimer $8 → $7 Maintains Outperform 09/07/2023 98.02% Cantor Fitzgerald → $4 Reite

BenzingaMar 20 07:13 ET

Earnings Call Summary | Corvus Pharmaceuticals(CRVS.US) Q4 2023 Earnings Conference

The following is a summary of the Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript:Financial Performance:Data unavailable.Business Progress:Data unavailable. Please provide the det

moomoo AIMar 19 21:15 ET · Conference Call

Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2

Corvus Pharmaceuticals (CRVS) said Tuesday it expects to start a phase 1 study of soquelitinib in patients with moderate to severe atopic dermatitis in Q2. Corvus expects to enroll 64 patients who hav

MT NewswiresMar 19 17:32 ET

Corvus Pharma Q4 EPS $(0.14) Misses $(0.12) Estimate

Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 33.33 percent increase over losses of $(0.

BenzingaMar 19 16:04 ET

Corvus Pharmaceuticals GAAP EPS of -$0.14 Misses by $0.01

Seeking AlphaMar 19 16:04 ET

Corvus Pharma: Soquelitinib Advancing Towards Initial Enrollment for Registrational Phase 3 Clinical Trial for PTCL and Randomized Phase 1 Clinical Trial for Atopic Dermatitis >CRVS

Corvus Pharma: Soquelitinib Advancing Towards Initial Enrollment for Registrational Phase 3 Clinical Trial for PTCL and Randomized Phase 1 Clinical Trial for Atopic Dermatitis >CRVS

Dow JonesMar 19 16:04 ET

Press Release: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical t

Dow JonesMar 19 16:02 ET